Aditxt (ADTX)
Develops immune, diagnostic, infectious disease, women's health, and oncology programs.
Something off on this page? Send us feedback.
Aditxt is a Nasdaq-listed platform that develops and acquires early-stage health technologies. Its subsidiaries focus on immune modulation, mitochondrial DNA diagnostics, infectious disease, women's health, and precision oncology.
Aditxt, Inc. is a health innovation platform headquartered in Mountain View, California. Its operating model is to form, license, acquire, and support subsidiaries around health technologies rather than sell one mature product line. Adimune is advancing ADI-100, an immune modulation candidate built on apoptotic DNA immunotherapy and aimed at inducing immune tolerance. Pearsanta develops mitochondrial DNA and other molecular diagnostics, including blood-based candidates for prostate cancer and endometriosis, supported by a CLIA/CAP laboratory.
Adivir is focused on antiviral and antimicrobial programs, while Adifem keeps a women's health mandate after the terminated Evofem merger. In 2026, Aditxt also acquired Ignite Proteomics, adding a commercial-stage precision oncology platform that measures protein activity to support therapy selection. Many programs still depend on clinical validation, regulatory clearance, partner execution, financing, and Nasdaq compliance.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $268.9K · Total debt $4.2M · Total assets $13.9M · Shareholders' equity −$33.3M
- Revenue
- $12.2K
- Operating income
- −$4.4M
- Net income
- −$15.9M
No dividends on record.
| Insiders2 holders · as of Jun 23, 2026 | 12.26% | 100.0K shares | |
| Strategic holders1 holder · as of Jun 15, 2026 | 0.02% | 165 shares | |
| Otherremainder | 87.72% | 715.8K shares |
815.9K company shares as of Sep 3, 2026 · holders as of their latest filing
Two share counts disagree (815.9K in the company's Sep 3, 2026 report, 997.98M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Wey Ann Tai1Insider10 percent owner | 12.26% | 100,000 | Form 4filed Jun 23, 2026 ↗ |
Bank of America Corp /DE/Strategic10 percent owner | 0.02% | 165 | Form 4filed Jun 15, 2026 ↗ |
Brian Michael BradyInsiderdirector | 0.00% | 0 | Form 4filed Dec 19, 2025 ↗ |
Altium Growth GP, LLCStrategic | —2.40% of class, as filed | — | 13G/Afiled Feb 16, 2021 ↗ |
Burciu Emil CristianInsider | —5.50% of class, as filed | — | 13Gfiled Jun 23, 2026 ↗ |
| See all 25 → | |||
- Reported at 0.00% on Jun 24, 2026, under the 5% line, so no further filing is required.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 23, 2026 | Takeover Time 2026 LLC | 10 percent owner | −3,420,439 | $0.0200 |
| Jun 22, 2026 | HRT Financial LP | 10 percent owner | −5,120,480 | $0.0180 |
| Jun 18, 2026 | HRT Financial LP | 10 percent owner | +7,340,178 | $0.0130 |
| Jun 17, 2026 | DRW Securities, LLC | 10 percent owner | −126,772 | $0.0079 |
| Jun 16, 2026 | HRT Financial LP | 10 percent owner | −3,132,480 | $0.0130 |
Not reported.